Literature DB >> 30793870

Treat-to-target in rheumatoid arthritis: Evaluating the patient perspective using the Patient Opinion Real-Time Anonymous Liaison system: The RA T2T PORTAL study.

Helen Benham1, Merrin Rutherford2, Sandra Kirby3, Simon Stebbings4, Douglas White5, Dalice Sim6, Andrew Harrison2.   

Abstract

OBJECTIVES: To determine the level of agreement among patients with rheumatoid arthritis (RA) with the principles and recommendations of the treat-to-target (T2T) initiative in New Zealand (NZ) and to further explore specific patient opinions via online iterative surveys.
METHODS: Participants with RA were recruited from rheumatology clinics in NZ and invited to receive and reply to surveys administered via the Patient Opinion Real-Time Anonymous Liaison (PORTAL) system. An enrolment survey recorded demographics, disease duration and treatment and then RA T2T surveys were administered weekly. A Likert scale 1-5 measured agreement with the principles and recommendations and further surveys explored responses of interest identified by investigators from each prior survey.
RESULTS: One hundred and ninety patients consented to participate in PORTAL and 132 in the RA T2T surveys. Level of agreement with RA T2T principles was: 93.3% to 99.3% and to the recommendations: 77.3%-100%. The lowest level of agreement 77.3% was with recommendation 8, 3 monthly treatment adjustment, and the highest was 100% agreement with recommendation 10, shared decision-making. Patients agreed less with low disease activity as the target compared with remission (91.4% and 98%). Despite high-level agreement for the use of a disease activity score (95.7%), 23% did not feel the individual components reflected their disease control. Patients rated difficulty coping, erosions on imaging, health-related quality of life and pain all significantly higher than C-reactive protein as indicators of worsening arthritis.
CONCLUSIONS: Despite a high level of patient agreement with RA T2T this study highlights the importance of patient engagement in the RA T2T process to individualize therapy adjustments, make shared decisions and decide on targets that accurately reflect disease control according to patients.
© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  rheumatoid arthritis; shared decision making; treat-to-target

Year:  2019        PMID: 30793870     DOI: 10.1111/1756-185X.13514

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  4 in total

1.  Fears about COVID-19 and perceived risk among people with rheumatoid arthritis or ankylosing spondylitis following the initial lockdown in Aotearoa New Zealand.

Authors:  Gareth J Treharne; Grace Johnstone; Benjamin D Fletcher; Roisin S M Lamar; Douglas White; Simon Stebbings; Andrew Harrison
Journal:  Musculoskeletal Care       Date:  2021-08-13

Review 2.  Implementing models of care for musculoskeletal conditions in health systems to support value-based care.

Authors:  Robyn Speerin; Christopher Needs; Jason Chua; Linda J Woodhouse; Margareta Nordin; Rhona McGlasson; Andrew M Briggs
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-07-25       Impact factor: 4.098

3.  Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis.

Authors:  Borja Hernández-Breijo; Chamaida Plasencia-Rodríguez; Victoria Navarro-Compán; Carlota García-Hoz; Israel Nieto-Gañán; Cristina Sobrino; Javier Bachiller-Corral; Mariana Díaz-Almirón; Ana Martínez-Feito; Teresa Jurado; Paloma Lapuente-Suanzes; Gema Bonilla; Cristina Pijoán-Moratalla; Garbiñe Roy; Mónica Vázquez-Díaz; Alejandro Balsa; Luisa M Villar; Dora Pascual-Salcedo; Eulalia Rodríguez-Martín
Journal:  Front Med (Lausanne)       Date:  2021-06-17

Review 4.  New galaxies in the universe of shared decision-making and rheumatoid arthritis.

Authors:  Jennifer L Barton; Simon Décary
Journal:  Curr Opin Rheumatol       Date:  2020-05       Impact factor: 4.941

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.